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Many mammalian b-tubulin mutations that confer
paclitaxel resistance have been characterized, but little
is currently known about the role of a-tubulin muta-
tions in drug resistance. Previous studies using two-
dimensional gel electrophoresis showed that a-tubulin
mutations occur with a frequency equal to b-tubulin
mutations among CHO cells selected for resistance to
paclitaxel but the identities of those mutations are
largely unknown. We have now sequenced the major
a-tubulin gene in several paclitaxel resistant CHO cell
lines with lesions in genomic DNA and identified five
mutations that predominately affect the amino terminal
part of the protein. We also used random mutagenesis
and transfection of a-tubulin cDNA to select further
paclitaxel resistant mutants in an effort to remove
genomic constraints that may limit the diversity of
mutations. This approach led to the identification of
16 additional mutations that were distributed through-
out the a-tubulin sequence. The mutations were con-
firmed as sufficient to confer resistance by site-directed
mutagenesis, and they acted by a mechanism that
involved reductions in microtubule assembly. One
mutation prevented the acetylation of a-tubulin but
otherwise produced a phenotype similar to the other
mutations. A scan of the literature revealed that a sig-
nificant number of drug resistance mutations overlap
or lie close to lesions that have been reported in
patients with brain disorders suggesting that alterations
in microtubule assembly underlie both cellular resist-
ance and developmental defects. VC 2013 Wiley Periodicals, Inc.
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Introduction
Microtubules are important targets for cancer chemo-therapeutic drugs. These cytoskeletal structures,
formed from heterodimers of a- and b-tubulin, are needed
for many critical cellular functions such as vesicle transport,
cell motility, and cell division. Because of their importance
for normal cell function, plants and lower organisms have
evolved numerous small organic molecules that bind to tubu-
lin and interfere with microtubule assembly and function.
These include classical inhibitors such as colchicine which is
used in the management of gout, as well as more recently dis-
covered compounds used in cancer therapy. For example,
vinblastine and vincristine have been used since the 1950s to
treat hematological malignancies such as leukemia and
Hodgkin’s lymphoma as well as a wide variety of solid
tumors. More recently, taxanes such as paclitaxel and doce-
taxel have proven to be highly effective for the treatment of
breast and ovarian cancer, head and neck tumors, lung can-
cer, and a number of other diseases. Because of the effective-
ness of these agents, the discovery of molecules targeting the
microtubule cytoskeleton remains an important area of drug
development and many of these new compounds are cur-
rently in clinical trials [Dumontet and Jordan, 2010].
Drugs that interfere with microtubule function can be
placed into one of two main groups based on their effects
on microtubule assembly when present at high concentra-
tions. Many of the compounds including colchicine, vin-
blastine, and vincristine inhibit the assembly of tubulin
into microtubules whereas the second group of com-
pounds including paclitaxel, epothilones, laulimalide, and
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peloruside promote tubulin assembly and stabilize micro-
tubules to disassembly. The fact that both inhibition and
stimulation of microtubule assembly is toxic to cells is a
reflection of the importance of microtubule behavior in
cell division. Microtubules are nucleated at the centro-
some, an organelle located near the nucleus, and grow
out to the cell periphery by adding subunits to the grow-
ing plus-end. Once formed, the microtubules constantly
remodel by undergoing stochastic episodes of growth and
shrinkage at their plus-ends, a behavior known as
dynamic instability [Mitchison and Kirschner, 1984].
When present at low concentrations, all microtubule tar-
geted drugs that have been tested interact with the plus-
ends and suppress dynamic instability [Jordan and
Wilson, 2004], a finding that seems at odds with the abil-
ity of various drugs to either enhance or inhibit microtu-
bule assembly. However, at higher concentrations these
drugs also interact with microtubule minus-ends that are
mainly embedded in the centrosome or spindle poles.
Microtubule depolymerizing drugs have been shown to
increase the frequency at which minus-ends detach from
the centrosome [Yang et al., 2010], whereas tubulin-
polymerizing drugs decrease that frequency [Ganguly
et al., 2010]. Free minus ends have been seen to shorten
but not elongate thereby increasing the rate of microtu-
bule turnover [Keating et al., 1997; Yang et al., 2010].
Thus, the effects of the drugs at the minus-end are con-
sistent with their known effects on microtubule assembly.
Cancer patients are generally treated with high concen-
trations of microtubule agents that interfere with spindle
function and inhibit cell proliferation. While this
approach has been successful for treating a variety of
tumors, patients commonly relapse and become insensi-
tive to further treatment. Although the mechanisms
behind the insensitivity of tumor cells to drug treatment
in patients is not well understood, cell culture studies
have identified many b-tubulin mutations that are able to
confer resistance to the drugs that are commonly used
[Huzil et al., 2007; Yin et al., 2012]. Much less is known
about the potential role of a-tubulin mutations in drug
resistance. Early studies suggested that a-tubulin muta-
tions are as common as b-tubulin mutations in CHO
cells selected for paclitaxel resistance [Schibler and Cabral,
1986], but to date only one a-tubulin mutation from a
paclitaxel resistant cell line has been identified by
sequencing [Martello et al., 2003]. Several additional
mutations in a-tubulin have been identified in cell lines
selected for resistance to drugs that destabilize microtu-
bules [Hari et al., 2003; Loganzo et al., 2004; Poruchyn-
sky et al., 2004]. To further explore the kinds of
a-tubulin mutations that can confer drug resistance, we
sequenced previously isolated paclitaxel resistant cell lines
with mutations in genomic DNA and created new pacli-
taxel resistant cell lines by random mutagenesis and trans-
fection of an a-tubulin cDNA. The properties of the
mutants and the locations of the tubulin alterations
strongly indicate that the mutations confer paclitaxel
resistance by affecting longitudinal and lateral interactions
required for microtubule assembly.
Results
Genomic a-Tubulin Mutations are Concentrated
near the N-Loop
Many mammalian b-tubulin mutations have been
described that alter the sensitivity of cells to drugs that can
influence microtubule assembly (reviewed in [Huzil et al.,
2007; Yin et al., 2012]). Most of the mutations produce
similar phenotypes. Thus, cells selected for resistance to
paclitaxel (a microtubule stabilizing drug) are frequently
seen to exhibit cross resistance to other microtubule stabiliz-
ing drugs but enhanced sensitivity to drugs that destabilize
microtubules [Schibler and Cabral, 1986; Yin et al., 2010].
Conversely, cells selected for resistance to colcemid or vin-
blastine are frequently cross resistant to other destabilizing
drugs but exhibit enhanced sensitivity to stabilizing drugs
[Hari et al., 2003; Minotti et al., 1991]. Paclitaxel resistant
cell lines have less microtubule polymer than normal,
whereas colcemid and vinblastine resistant cell lines have
more polymer than normal suggesting that the mutations
are acting by altering the stability of the microtubules
[Cabral et al., 1986; Minotti et al., 1991; Cabral, 2008].
Recently, the molecular basis of this altered stability has
been traced to the frequency at which microtubules detach
from centrosomes and spindle poles [Ganguly and Cabral,
2011]. Microtubule disrupting drugs increase this fre-
quency while microtubule stabilizing drugs decrease the fre-
quency of microtubule detachment [Ganguly et al., 2010;
Yang et al., 2010]. Drug resistance mutations oppose these
actions; i.e., paclitaxel resistance mutations increase the fre-
quency of detachment and colcemid resistance mutations
decrease microtubule detachment.
Mutations in b-tubulin can also produce resistance by
decreasing the affinity of a drug for tubulin. This is most
commonly seen in lower organisms that can grow in the
haploid state [Sheir-Neiss et al., 1978; Thomas et al.,
1985], but has also been observed in mammalian cells
selected through multiple rounds of selection. These latter
mutants contain lesions in the major expressed b-tubulin
gene (b1-tubulin) and invariably contain additional lesions
that may include loss of expression of the remaining wild-
type b1-tubulin allele [Giannakakou et al., 1997, 2000;
Begaye et al., 2011; Kanakkanthara et al., 2011]. These
multistep mutants commonly have more limited drug
cross-resistance and exhibit higher levels of resistance than
cells with mutations that act by altering microtubule
assembly.
In contrast to the information about b-tubulin muta-
tions, little is known about the role of a-tubulin mutations
in drug resistance. To remedy this situation, we sequenced
seven CHO cell lines that had been selected in a single step
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for resistance to paclitaxel [Schibler and Cabral, 1986]. Five
of these cell lines had unique mutations in a-tubulin that
are summarized in Table I; the remaining two cell lines car-
ried mutations (E22K and R79C) that were redundant. Of
the five newly identified mutations, all but one affected
amino acids located near the N-loop of a-tubulin, a region
proposed to be of importance for lateral interactions
between protofilaments in microtubule assembly [Nogales
et al., 1999]. Although most of the mutations affected
charged residues, this outcome likely reflected the fact that
we focused most of our sequencing efforts on mutant cell
lines that exhibited alterations in a-tubulin mobility by
two-dimensional gel electrophoresis [Schibler and Cabral,
1986].
Random Mutagenesis Identifies Dispersed
a-Tubulin Mutations That Confer Paclitaxel
Resistance
The preponderance of mutations near the N-loop of
a-tubulin led us to question whether this was a particularly
important region for the generation of resistance to pacli-
taxel or if genomic constraints such as the level of
a-tubulin expression limited the isolation of mutations
affecting other regions of the protein. To address this issue,
we turned to a random mutagenesis approach in which
mutations were introduced into an HA-tagged a1-tubulin
cDNA using an error prone Taq polymerase. Transfection
of CHO cells with a heterogeneous population of these
cDNAs followed by selection with a toxic concentration of
paclitaxel (300 nM) produced a large number of resistant
colonies that were randomly isolated and used to establish
independent cell lines.
To determine whether the drug resistance of these clones
was conferred by a mutant form of transfected HAa1-
tubulin or by other genomic alterations, we made use of the
fact that the transfected cDNA was under the transcrip-
tional control of a tetracycline repressible promoter [Gossen
and Bujard, 1992]. Ten randomly isolated clones were
tested for their ability to form colonies in the selecting con-
centration of paclitaxel (300 nM) in the presence or absence
of 1 mg ml21 tetracycline. If resistance was due to the
expression of a mutant form of HAa1-tubulin, it was pre-
dicted that the cells should be able to grow in paclitaxel
when tetracycline was absent, but not when it was present
to repress the transcription of the transfected cDNA. This
prediction was confirmed by the results shown in Fig. 1.
Most of the clones failed to form viable colonies in pacli-
taxel when tetracycline was present and the remainder
formed fewer colonies that were smaller in size indicating
the production of insufficient mutant HAa1-tubulin to
allow normal growth in the drug. The observation that
some clones were able to survive paclitaxel to some extent
even in the presence of tetracycline was not surprising as we
have repeatedly seen that tetracycline repression of trans-
gene expression can vary considerably from clone to clone
[Bhattacharya and Cabral, 2004; Ganguly et al., 2011].
Nonetheless, the isolation of clones whose ability to grow
in paclitaxel was clearly regulated by tetracycline indicated
that the transfected HAa1-tubulin was responsible for
resistance in at least some of the cell lines.
Table I. Amino Acid Substitutions in a1-Tubulina
Genomic mutations Random mutagenesis
Mutation Cell line Location Mutation Clone Location
E22K Tax 5–6 H1 S48P Ptx 12 H1/S2 (N loop)b
S48F Tax 9-2 H1/S2 (N loop)b F138L Ptx 2 S4
E77K Tax 11-6 H2c S151P Ptx 6 H4
R79C Tax 2–3 H2 L167P, G410S Ptx 7 H4/S5, H11’/H12c
K394E Tax 8-2 H11c L227I, I234T Ptx 5 H7
I234T Ptx 4 H7
E279G Ptx 1 S7/H9 (M loop)b
L286P Ptx 3 S7/H9 (M loop)b
E297G, I335V Ptx 10 H9/S8b, H10b
D327Y Ptx 8 H10b
Y399H Ptx 9 H11c
K394R, M413I, E414G Ptx 11 H11c, H11’/H12c
aPaclitaxel resistant mutants were isolated from CHO cells by classical genetics (genomic mutations) or by transfection of randomly mutagenized
cDNA. H, helix; S, beta sheet; H/S, S/H, or H/H are intervening loops.
bLateral contacts.
cLongitudinal contacts.
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Further evidence that the transfected cDNA was respon-
sible for drug resistance came from DNA sequencing. DNA
was isolated from 12 random colonies and the integrated
HAa1-tubulin cDNA was amplified using primers specific
for the 50 untranslated region of the gene together with a
downstream plasmid sequence. A band of the appropriate
size for HAa1-tubulin cDNA was obtained and sequencing
demonstrated that the cDNAs contained mutations (Table
I). Interestingly, two of the mutations identified by random
mutagenesis, S48P and K394R, affected residues that were
also found to be altered in two of the mutants isolated by
classical methods. This overlap suggests that a limited num-
ber of amino acids in a-tubulin may be involved in generat-
ing resistance to paclitaxel.
Double Mutations Confer Resistance
Individually
Although most of the cDNA sequences from paclitaxel
resistant clones in the random mutagenesis experiment con-
tained a single mutation, clones Ptx 5, Ptx 7, and Ptx 10
had two mutations and clone Ptx 11 had three. This raised
the question of whether each mutation could confer resist-
ance individually or if the combination of mutations was
necessary. To resolve this issue, each of the mutations in Ptx
7 and Ptx 10 were introduced into HAa1-tubulin cDNA
individually and in tandem by site-directed mutagenesis.
Wild type CHO cells were transfected with these cDNAs
and tested for their ability to grow in 300 nM paclitaxel in
the presence or absence of tetracycline (Fig. 2). The control
cells transfected with wild-type HAa1-tubulin cDNA were
only able to form colonies when paclitaxel was absent. In
contrast, each of the four mutations identified in these two
clones was capable of allowing cell proliferation in paclitaxel
when tetracycline was absent indicating that in the clones
with multiple mutations, the individual mutations were suf-
ficient to confer resistance. The growth in paclitaxel was
inhibited when tetracycline was added to repress transcrip-
tion of the mutant cDNA. The I335V mutation was the
weakest in its ability to allow growth in paclitaxel suggest-
ing that by itself, higher levels of expression are likely to be
needed for resistance.
The triple mutant Ptx 11 was not analyzed in a similar
manner and we cannot be certain that the mutations are
able to confer resistance individually. However, it is likely
that the identified mutations are involved in resistance
given their proximity to other mutations that have been
verified by transfection or reversion analysis. For example,
K394R represents the same locus as the K394E mutation in
Tax 8-2 (Table I). Even though K394R is a conserved sub-
stitution, it has been observed that conserved substitutions
in b-tubulin can alter drug sensitivity and it is likely that a
similar situation holds for a-tubulin [Wang et al., 2006;
Yin et al., 2012]. Similarly, M413I and E414G of Ptx 11
are very close to the G410S mutation of Ptx 7 that was veri-
fied by transfection.
Fig. 1. Tetracycline regulation of paclitaxel resistance in cell
lines derived by transfection of randomly mutagenized
HAa1-tubulin cDNA. Cells transfected with wild-type HAa1-
tubulin cDNA (HAaWT) or transfected with randomly muta-
genized HAa1-tubulin cDNA and selected for paclitaxel resist-
ance (Ptx cell lines 1–10, see Table I) were seeded in duplicate
into 24-well dishes and grown for 7 days until visible colonies
appeared. To determine whether mutant HAa1-tubulin produc-
tion was necessary for drug resistance, the medium contained
300 nM paclitaxel in the absence or presence of 1 mg ml21 tet-
racycline (Tet), an antibiotic used to repress transcription of the
transfected cDNA. The dishes were stained with methylene blue
and photographed.
Fig. 2. Double mutations can confer resistance to paclitaxel
individually. The double mutations found in cell lines Ptx 7
and Ptx 10 were retested by creating each of the indicated
mutations individually and in tandem by site-directed mutagen-
esis of HAa1-tubulin cDNA. These were transfected into wild-
type CHO cells and compared to cells transfected with a wild-
type (WT) HAa1-tubulin cDNA. Stable cell lines were gener-
ated by selection for resistance to G418. Each cell line was
seeded into triplicate wells of six-well dishes and grown for 7
days in the presence (1) or absence (2) of 300 nM paclitaxel
(Ptx) and 1 mg ml21 tetracycline (Tet). Note that the first well
in each case was used to control for the number of cells seeded
and contained 50-fold fewer cells than the other two but was
not treated with paclitaxel. The dishes were stained with meth-
ylene blue and photographed.
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Paclitaxel Resistance Mutations Alter the
Appearance of the Microtubule Network
To determine whether the mutant HAa1-tubulins were
capable of assembly into microtubules and whether they
affected microtubule organization, the drug resistant cells
were examined by immunofluorescence using an antibody
specific for the HA tag. In all cases the HAa1-tubulin was
seen to assemble into microtubule arrays. Cells transfected
with wild-type HAa1-tubulin cDNA exhibited normal
appearing dense microtubule networks that originated from
the centrosomal area located near the nucleus (Fig. 3A).
Cells transfected with the indicated mutant HAa1-tubulin
cDNAs had a similar organization of microtubules, but in
many cases the network appeared to be less dense (Figs.
3B–3G). This was especially noticeable for cells transfected
with the double mutation L167P and G410S (Fig. 3D)
indicating that this was a particularly disruptive pair of
mutations and/or the cDNA was expressed at a very high
level. Similar apparent decreases in microtubule density
were seen in the original Ptx cell lines listed in Table I (Sup-
porting Information Fig. S1).
Paclitaxel Resistant Cells Have Reduced
Amounts of Microtubule Polymer
The appearance of the mutant cells in Fig. 3 suggested that
they have less microtubule polymer than normal cells. To
confirm this prediction, the relative amounts of polymer
were compared in cell lines transfected with wild-type and
mutant HAa1-tubulin cDNAs. The procedure involved
lysing cells in a microtubule stabilizing buffer, separating
the polymer from soluble tubulin by centrifugation, and
quantifying the amount of tubulin in each fraction [Minotti
et al., 1991]. The percentage of total tubulin in the micro-
tubule fraction was then calculated for each cell line and
the results are summarized in Fig. 4. Western blot analysis
demonstrated that wild-type and mutant forms of HAa1-
tubulin were able to assemble and appear in the microtu-
bule fraction (P) in a ratio similar to soluble tubulin (S)
indicating that there was little or no preferential assembly
of the mutant subunit into, or exclusion from, the
Fig. 3. Microtubule immunofluorescence in paclitaxel resist-
ant cell lines. The transfected cell lines described in Fig. 2 were
grown for 3 days on glass coverslips without paclitaxel or tetra-
cycline. The cells were then extracted briefly with a microtubule
stabilizing buffer, fixed in methanol, and stained with an anti-
body specific for the HA tag. Bar5 10 mm.
Fig. 4. Tubulin assembly in paclitaxel resistant cells. The
mutant transfected cell lines described in Fig. 2 were maintained
in 300 nM paclitaxel (no tetracycline) and then incubated over-
night without paclitaxel or tetracycline, lysed with a microtubule
stabilizing buffer, and centrifuged to separate microtubule poly-
mer in the pellet (P) from soluble tubulin in the supernatant
(S). A control cell line (WT) transfected with wild-type HAa1-
tubulin cDNA was maintained in drug-free media throughout.
An equal amount of a bacterial cell extract containing glutathi-
one-S-transferase-conjugated a-tubulin (GSTa) was added to
each fraction to control for losses in subsequent steps and the
proteins were separated by SDS gel electrophoresis. The proteins
were then transferred onto a nitrocellulose membrane and
probed with an antibody to a-tubulin. An example of such an
experiment is shown in (A). HAa, transfected wild-type or
mutant HAa-tubulin; a, endogenous a-tubulin. Each experi-
ment was run in triplicate three times and the results were
quantified as the fraction of tubulin in the pellet (P) relative to
the total tubulin (P1 S) and expressed as a percentage (B). Sig-
nificance of the differences from the control (WT) was deter-
mined by the student’s t test. *, P< 0.05; **, P< 0.01.
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microtubules (Fig. 4A). However, the relative amount of
cellular tubulin appearing in the pellet was reduced in all
the mutant cell lines. This result is consistent with a mecha-
nism in which incorporation of the mutant subunit pro-
duces resistance by interfering with microtubule assembly
[Cabral, 2001, 2008; Ganguly and Cabral, 2011]. The per-
centage of total a-tubulin (endogenous and transfected)
assembled into microtubules was about 40% for cells trans-
fected with wild-type HAa1-tubulin (Fig. 4B), a value con-
sistent with previously reported values for tubulin assembly
in wild-type or HAb1-tubulin transfected CHO cells
[Minotti et al., 1991; Gonzalez-Garay et al., 1999; Hari
et al., 2003]. In contrast, all of the cell lines transfected
with mutant HAa1-tubulin exhibited reduced assembly of
tubulin ranging from 20 to 31% of total tubulin thus con-
firming the visual impression derived from Fig. 3. Similar
results were obtained for the original paclitaxel resistant cell
lines obtained by transfection where microtubule assembly
ranged from 13 to 30% of total tubulin (Supporting Infor-
mation Fig. S2). The reduced extent of microtubule assem-
bly in paclitaxel resistant cells carrying mutations in
a-tubulin is also consistent with results previously reported
in paclitaxel resistant cell lines carrying mutations in
b-tubulin [Gonzalez-Garay et al., 1999].
Paclitaxel Resistance Mutations Often Interfere
With Cell Division
Although all mutants grew well in the presence of pacli-
taxel, it was noted than many of them grew poorly when
the drug was removed from the culture medium. This
property, called paclitaxel dependence, was previously noted
for both a- and b-tubulin mutants and was shown to result
from defects in spindle formation and function [Cabral,
1983; Cabral et al., 1983; Schibler and Cabral, 1986].
Although many cell lines with spindle defects become
blocked at mitosis, others such as CHO cells slip through
the spindle checkpoint and reenter the next cell cycle as
large multinucleated cells [Abraham et al., 1983; Kung
et al., 1990]. An example of this behavior is illustrated in
Fig. 5 which shows a mixture of untransfected cells and cells
that express HAa1-tubulin with an L167P mutation. By
appropriately adjusting the antibody concentrations used
for immunofluorescence, the transfected cells appear green,
yellow, or orange depending on the level of mutant protein
produced while the untransfected cells appear red. Thus,
transfected and nontransfected cells can be compared
directly in the same microscopic field of view. When the
cells were cultured without paclitaxel for 3 days, the
untransfected (red) wild-type cells had a normal appearance
whereas the green transfected cells were frequently larger
and contained multiple or oddly shaped nuclei suggestive
of cells that had failed to properly segregate chromosomes
during mitosis and progressed into G1 phase without divid-
ing (Fig. 5A). In contrast, a similar cell mixture cultured in
the presence of paclitaxel had normal looking transfected
cells (green) but untransfected cells (red) exhibited symp-
toms of paclitaxel toxicity; i.e., they were larger, had a very
dense microtubule network, and contained multiple nuclei
characteristic of cells with problems in chromosome segre-
gation and cell division (Fig. 5B). The severity of the
mitotic defects noted in the paclitaxel resistant cell lines var-
ied considerably depending on the potency of the mutation
and the level of mutant protein production. In general, cells
with the lowest assembly of microtubules (see Fig. 4 and
Supporting Information Fig. S2) had the most severe
defects when paclitaxel was removed from the medium.
Mutation E22K Interferes With Acetylation
of a-Tubulin Lysine 40
All of the paclitaxel resistant cell lines had similar pheno-
types regardless of the location of their mutations in
a-tubulin. However, cell line Tax 5–6 was found to have a
unique defect that affected its ability to acetylate mutant,
but not wild-type, a-tubulin. The defect was found using
two-dimensional gel electrophoresis of cell extracts (Fig. 6).
An autoradiogram of a metabolically labeled wild-type cell
extract showed the separation of a-tubulin from b-tubulin
and vimentin. In this gel system a-tubulin resolves as two
spots of similar isoelectric point running with slightly faster
mobility than vimentin in the SDS polyacrylamide gel
dimension [Boggs and Cabral, 1987; Minotti et al., 1991;
Gonzalez-Garay et al., 1999; Hari et al., 2003]. The two
spots for a-tubulin do not represent alternative gene prod-
ucts but rather appear to result from impurities in SDS and
the pH of the gel buffers that are used (unpublished obser-
vations). Both a-tubulin spots stain with DM1A, an anti-
body that recognizes a-tubulin, and with 6–11b-1, an
antibody specific for a-tubulin that is acetylated at residue
Fig. 5. Paclitaxel dependence of transfected cell lines. A sta-
ble G418 resistant cell line expressing HAa1-tubulin cDNA
with the L167P mutation was mixed with untransfected cells
and grown on glass coverslips for 3 days without (A) or in the
presence of 100 nM paclitaxel (B). The cells were extracted
with a microtubule stabilizing buffer, fixed in methanol, and
stained with antibodies to the HA tag and an Alexa 488-
conjugated secondary antibody (green), antibodies to a-tubulin
and an Alexa 594-conjugated secondary antibody (red), and
DAPI to stain the DNA (blue). Bar5 20 mm.
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lysine 40 [LeDizet and Piperno, 1987; Piperno et al.,
1987]. The isoelectric point of the acetylated tubulin is
more acidic as expected for the neutralization of the charge
on lysine 40. This shift in isoelectric point can be demon-
strated by the mixing experiment in Fig. 6 in which both
antibodies were used to stain the western blot
simultaneously.
The autoradiogram for Tax 5–6 had the same spots that
were seen in the wild-type cell extract, but contained two
additional spots representing a-tubulin with the E22K
mutation migrating at a more basic isoelectric point. The
identification of the new spots as a-tubulin was confirmed
by the reaction with DM1A (Fig. 6). Some additional
weaker “spots” on this blot are part of a streak that indicates
incomplete focusing of the a-tubulin in this particular sam-
ple. When a similar blot was probed with the 6–11b-1 anti-
body, only the wild-type a-tubulin reacted as confirmed by
probing a blot with a mixture of the two antibodies. This
experiment demonstrated that Tax 5–6 contains the neces-
sary enzymes to carry out acetylation of tubulin, but that
the E22K mutation interferes with the acetylation of
lysine 40.
In contrast to Tax 5–6, another mutant, Tax 8-2, pro-
duced a mutant protein that reacted with antibody 6–11b-
1 (Fig. 6). Tax 8-2 has a K394E mutation in a-tubulin that
causes the protein to focus at a more acidic isoelectric point.
Unlike the mutant protein in Tax 5–6, the Tax 8-2 mutant
protein reacted with both the DM1A and 6–11b-1 antibod-
ies demonstrating that it was acetylated at lysine 40. Screen-
ing other mutants with mobility shifts of a-tubulin on two-
dimensional gels in this manner uncovered no additional
cell lines with a defect in acetylation.
Discussion
The results from this study significantly expand the collec-
tion of a-tubulin mutations found in drug resistant mam-
malian cells. Several previously published mutations have
come from cell lines selected for resistance to drugs that
inhibit microtubule assembly, and only one from a cell line
resistant to paclitaxel (Table II). All the previous mutations
except those for resistance to colcemid and vinblastine were
found in cell lines that had undergone multistep selections
and may therefore have multiple lesions contributing to the
resistance phenotype. For example an S379R substitution
in a-tubulin reported in paclitaxel resistant A549 cells was
found along with altered levels of the microtubule interact-
ing protein stathmin, and the relative contributions of these
changes to the mutant phenotype are unknown [Martello
et al., 2003]. Moreover, no known mutations in a-tubulin
have been verified as necessary and sufficient to produce
drug resistance using methods such as reversion analysis or
transfection of mutant cDNA.
The mutations described in our current studies were
found in mutant cell lines derived in single step selections;
thus, all the mutations are likely to be responsible for the
drug resistance phenotype. In most cases this expectation
was verified by selecting revertant cell lines that regained
sensitivity to paclitaxel [Schibler and Cabral, 1986] or by
recreating the phenotype in wild-type CHO cells via trans-
fection of cDNA carrying the mutation (e.g., Fig. 2). Pacli-
taxel resistance was unlikely to be caused by decreased
affinity of the drug for tubulin. This conclusion was
reached based on the theoretical argument that diminished
drug binding is a recessive phenotype that should not
appear in diploid cells as well as experimental evidence that
mammalian cells with reduced drug binding have been
accompanied by a loss of heterozygosity [Giannakakou
et al., 1997; Giannakakou et al., 2000; Begaye et al., 2011;
Kanakkanthara et al., 2011]. In contrast, our mutant cell
lines retain one (genomic mutants) or both (random muta-
genesis mutants) wild-type alleles and exhibit properties
such as reduced microtubule assembly and paclitaxel
dependence for growth that cannot be explained by drug
binding effects. The properties of our a-tubulin mutants
are consistent with the phenotypes of previously described
b-tubulin mutants and suggest a resistance mechanism in
Fig. 6. Mutant tubulin in Tax 5–6 is not acetylated. Wild-
type (WT) and paclitaxel resistant Tax 5–6 and Tax 8-2 CHO
cell lines (Table I) were metabolically labeled in 35S-methionine
and lysed in SDS. Proteins in the lysates were resolved by two-
dimensional gel electrophoresis and transferred to nitrocellulose
membranes. The membranes were exposed to X-ray film (ARG)
and stained with antibodies to a-tubulin (DM1A), acetylated
a-tubulin (6–11b-1), or a mixture of the two (Mix). The acidic
ends of the gels are oriented to the right and only the tubulin
area of the gels are shown. v, vimentin; a, a-tubulin; b, b-
tubulin; m, mutant a-tubulin; a*, acetylated a-tubulin; m*,
acetylated mutant a-tubulin. Note that by diluting the DM1A
antibody in the Mix, it stains the blots much less intensely,
allowing the acetylated a-tubulin to stand out and create a dou-
ble labeling effect.
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which the mutations alter microtubule assembly in a way
that counteracts the action of the selecting drug [Cabral,
2008; Ganguly and Cabral, 2011]. We previously reported
that alterations in a-tubulin are as frequent as alterations in
b-tubulin among cell lines selected for resistance to pacli-
taxel [Schibler and Cabral, 1986] and the new data
obtained with cell lines created by transfection of randomly
mutagenized cDNA confirm the involvement of a-tubulin
mutations in paclitaxel resistance. The data further show
that the phenotypes of the mutant cells and the mechanism
by which they have acquired resistance are similar for a-
and b-tubulin mutants.
One significant difference between the genomic muta-
tions in a-tubulin and the mutations identified by random
mutagenesis was their distribution. Whereas the genomic
mutations were largely restricted to the N-terminal region
of a-tubulin, the mutations identified by transfection of
mutagenized cDNA were distributed throughout the
sequence. The reason for this difference is unclear, but we
propose that it may result from the constraints imposed on
the expression of endogenous genes as opposed to the more
heterogeneous expression of transfected cDNAs. For exam-
ple, CHO cells have two copies of the a1-tubulin gene that
together account for about 70% of a-tubulin production
[Elliott et al., 1985, 1986]. A mutant allele would then
affect about 35% of the total tubulin. At this level of pro-
duction, a strong mutation might be so disruptive to micro-
tubule assembly that the cells would be unable to survive
under any conditions whereas a weak mutation might be
insufficiently disruptive to allow the cells to survive selec-
tion in paclitaxel. The transfection of mutagenized cDNAs
is free of such restrictions. A strong mutation could be
expressed at a low level whereas a weak mutation could be
expressed at a high level thus giving each the opportunity to
confer resistance yet maintain the viability of the cells in
the presence of the drug. Because transfection produces cells
with varying levels of expression, the addition of a toxic
drug allows cells that produce the right level of mutant pro-
tein to survive the selection while those that produce too
much or too little are lost. Similar arguments have been
made in the case of b-tubulin where most genomic muta-
tions were found in the H6/H7 loop of the protein but
mutations identified by transfection were distributed
throughout the sequence [Yin et al., 2012].
Of all the paclitaxel resistance mutations, only E77 has
been reported to form a direct contact with an adjacent
subunit in assembled microtubules but many of the altered
amino acid residues are close to regions of contact and are
likely to affect lateral or longitudinal interactions [Nogales
et al., 1999]. This observation is consistent with the conclu-
sion that the mutations produce drug resistance by altering
the assembly properties of tubulin. For example, residue
S48 was altered in mutants Tax 9-2 and Ptx 12 (Table I).
This residue is exposed on the surface of a-tubulin and lies
in the middle of the N-loop which has been proposed to
play a prominent role in lateral interactions between
a-tubulins on adjacent protofilaments (Fig. 7). Similarly,
E279 and L286 are located in the M-loop that appears to
interact with the N-loop to form the major lateral contacts
between protofilaments [Li et al., 2002]. Significantly,
Fig. 7. Distribution of mutations in a-tubulin. The structure
of an ab tubulin heterodimer was created with MacPymol
[DeLano, 2005] using the atomic coordinates published as
1TUB in the Protein Data Bank [Nogales et al., 1998]. Blue,
a-tubulin; magenta, b-tubulin; pink spheres, guanine nucleo-
tides; gray spheres, docetaxel (an analog of paclitaxel). The loca-
tions of genomic mutations are indicated in green and the
locations of mutations generated by random mutagenesis are
shown in red. Two of the lesions (affecting residues S48 and
K394) were found in both genomic and random mutants (see
Table I) and are indicated by yellow. The orientation of the het-
erodimer is shown relative to the1 (fast growing) and2 (slow
growing) ends, as well as to the outside and inside (lumen) of
the microtubule. The position of the N-loop (H1/S2 loop) is
labeled on the a subunit. (A) lateral view; (B) axial view from
the plus end. The b subunit was hidden from the axial view to
simplify the image. Amino acid substitutions found in the
mutant cell lines are labeled.
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mutations in both N and M loops have also been identified
in colcemid resistant cell lines (Table II) suggesting that
alterations that either strengthen or weaken the interprotofi-
lament interactions can produce resistance to drugs with
opposing actions on microtubule assembly. Other amino
acid substitutions located in structural elements that may
affect lateral contacts are indicated in Tables I and II.
Further mutations are predicted to perturb structural ele-
ments that form longitudinal contacts within the protofila-
ments, and these mutations are also indicated in Tables I
and II. In addition to E77 that is altered in Tax 11-6, a
prominent region of a-tubulin encompassing K394 to
E414 is altered in Tax 8-2, Ptx 7, Ptx 9, and Ptx 11 (Table
I) and is near the intradimer contact with b-tubulin. These
mutations could potentially alter the conformation of the
heterodimer and lead to weaker interdimer and lateral inter-
actions in the microtubule. More buried residues such as
L167, F138, and the core helix 7 residues L227 and I234
could also be acting by altering the conformation of tubu-
lin. The widely distributed mutations identified by random
mutagenesis indicate that diverse regions involved in micro-
tubule assembly can play a role in altering sensitivity to
paclitaxel and related drugs.
One unusual mutation was discovered in cell line Tax
5–6. The E22K mutation in these cells inhibited the abil-
ity of the altered HAa1-tubulin to be acetylated at lysine-
40. This defect did not arise from an alteration in the
acetylation machinery because the co-expressed wild-type
a-tubulin was acetylated normally. Instead, it seems likely
that the E22K alteration may affect the binding of the
acetyltransferase or it may alter the conformation of the
a-tubulin in such a way as to make it a poor substrate.
The significance of tubulin acetylation is still controver-
sial, but most studies indicate that it does not play a
major role in microtubule assembly or stability. Because
polymerized tubulin is the substrate for the acetyltransfer-
ase, acetylation is generally recognized as a marker for the
longevity of the microtubule; i.e., “older” microtubules
are more heavily acetylated than newly formed microtu-
bules [Janke and Bulinski, 2011; Westermann and Weber,
2003]. Consistent with these observations, we found no
unusual phenotype in Tax 5–6 in terms of its prolifera-
tion, microtubule assembly, or drug sensitivity compared
to other paclitaxel resistant mutants with normal tubulin
acetylation.
Finally, we wish to point out that similar microtubule
defects may underlie multiple phenotypes; for example, a
growing list of a- and b-tubulin mutations has recently
been shown to cause or contribute to a number of neuro-
logical disorders including lissencephaly, polymicrogyria,
and cerebellar hypoplasia [Tischfield et al., 2011]. We pre-
viously reported that b-tubulin mutations we and others
have found in drug resistant cell lines have also been
reported in developmental brain disorders [Yin et al.,
2012]. We now report that a similar situation occurs with
a-tubulin mutations (Table III). Although the number of
a-tubulin mutations available for comparison is more lim-
ited, we have already seen that an E55K mutation identified
in a colcemid and vinblastine resistant cell line (Table II)
was reported in a patient with lissencephaly (Table III), an
R390C mutation identified in a vinblastine resistant cell
line (Table II) has been reported in a patient with polymi-
crogyria (Table III), and an L286P mutation that confers
resistance to paclitaxel (Table I) coincides with an L286F
mutation reported in a patient with lissencephaly (Table
III). In addition, several more mutations causing brain dys-
genesis are adjacent or lie very close to mutations that cause
drug resistance (indicated in Table III). These observations
suggest that mutations affecting microtubule assembly can
produce pleiotropic effects encompassing both drug
Table II. Other Drug Resistance Mutations in a-Tubulin.
Mutation Phenotype Location Reference
A12S HtiR Helix 1 [Loganzo et al., 2004]
E55K CmdR N-loopa [Hari et al., 2003]
S165P HtiR H4/S5 loopa [Poruchynsky et al., 2004]
R221H HtiR H6/H7 loopb [Poruchynsky et al., 2004]
H283Y CmdR M-loopa [Hari et al., 2003]
S379R PtxR Sheet 10 [Martello et al., 2003]
A383V CmdR Helix 11b [Hari et al., 2003]
I384V HtiR Helix 11b [Poruchynsky et al., 2004]
R390C VlbR Helix 11b [Hari et al., 2003]
Abbreviations: HtiR, resistance to HTI-286 a synthetic analog of hemiasterlin; CmdR, resistance to colcemid; VlbR, resistance to vinblastine.
aLateral contacts.
bLongitudinal contacts.
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resistance and tissue formation and function. It is likely
that further overlaps will be found in future studies.
Materials and Methods
Materials
CHO tTA puro 6.6a cells expressing a tetracycline regu-
lated transactivator (tTA) were maintained at 37C in alpha
modified minimum essential medium (aMEM) supple-
mented with 5% fetal bovine serum (Atlanta Biologicals),
50 U ml21 penicillin, 50 mg ml21 streptomycin (Invitro-
gen), 10 mg ml21 puromycin, and 1 mg ml21 tetracycline
[Gonzalez-Garay et al., 1999]. CHO Ca1 cDNA (Gene-
Bank TM accession no. M12252.1) was cloned into pTOP-
neo which contains a minimal CMV promoter driven by
seven upstream copies of the tet operator [Gossen and
Bujard, 1992; Gonzalez-Garay et al., 1999]. The cDNA
was engineered to encode a nine amino acid hemagglutinin
antigen (HA) epitope tag (YPYDVPDYA) at the
C-terminal end of the protein to create the plasmid
pTOPHAa1. Chemicals and tissue culture media were
from Sigma–Aldrich unless otherwise stated.
Random Mutagenesis and Selection of
Paclitaxel Resistant Cell Lines
A random pool of HAa1-tubulin mutations were generated
using PCR reactions with an error-prone Taq polymerase
(Invitrogen, Carlsbad, CA) and two plasmid sequence pri-
mers (pTOPF2, 50-GAT CCC CCA TTA TTG AAG CA-
30 and pTOPR2, 50-CAG AAG CCA TAG AGC CCA
CC-30) that span the coding and regulatory sequences of
the cDNA. The Taq polymerase has an error rate of 8 3
1026; after 20 cycles under normal conditions, 16% of the
PCR products are expected to contain random mutations
with no hot spots (see the product manual). We obtained a
broad range of mutations by combining reactions from 30,
35, and 40 cycles. The mixed linear DNAs were purified
using a QIAprep 8 Miniprep Kit (Qiagen, Valencia, CA)
and then transfected into CHO tTApuro 6.6a cells using
Lipofectamine (Invitrogen) as described elsewhere [Gonza-
lez-Garay et al., 1999]. Transfected cells were reseeded into
six-well dishes, grown to 50% confluence, and treated with
300 ng ml21 paclitaxel in the absence of tetracycline to
allow expression of the transfected DNA. After 14 days,
visible colonies were isolated and grown in 24-well dishes
Table III. a-Tubulin Mutations Causing Human Brain Dysgenesis
Mutation Location Reference Mutation Location Reference
I5L S1 1 A270T S7 3
E55Ka N-loop 2 L286Fa M-loop 5
L92V S3 3 V303G H9/S8 7
V137Db S4 3 N329Sc H10 3
Y161H H4 4 M377Vc S10 3
I188L H5 5 R390Ca H11 3, 4
Y210C H6 1 L397Pc H11 8
D218Yc H6/H7 3 R402C,H,Lc H11/H11’ 2, 3, 5
V235Lb H7 4 S419L H12 5
I238V H7 6 R422C,H H12 2, 3, 8
P263T H8/S7 5 M425K H12 3
R264C H8/S7 5 G436R Disorderedd 8
aSame locus as a drug resistance mutation.
bAdjacent to a drug resistance mutation.
cWithin three amino acids of a drug resistance mutation.
dThis region near the carboxyl terminus of tubulin is disordered in the crystal structure.
1. [Jansen et al., 2011]
2. [Morris-Rosendahl et al., 2008]
3. [Kumar et al., 2010]
4. [Poirier et al., 2013]
5. [Poirier et al., 2007]
6. [Fallet-Bianco et al., 2008]
7. [Lecourtois et al., 2010]
8. [Bahi-Buisson et al., 2008]
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in the continued presence of 300 ng ml21 paclitaxel. As an
initial test for whether resistance was caused by the expres-
sion of exogenous a-tubulin, cells were seeded into 24-well
dishes containing 300 ng ml21 paclitaxel in the presence
and absence of 1 mg ml21 tetracycline and incubated for 7
days. Surviving colonies were stained by removing the
medium, rinsing the wells with PBS, and adding 0.1%
methylene blue for at least 1 h [Cabral et al., 1980]. The
wells were rinsed with water to remove excess stain and dig-
ital photographs were taken.
Immunofluorescence
Cells grown on sterile glass coverslips in aMEM without
tetracycline were rinsed briefly in PBS, pre-extracted with
microtubule buffer (MTB) (20 mM Tris-HCl, pH 6.8, 1
mM MgCl2, 2 mM EGTA, 0.5% NP-40 and 4 mg ml
21
paclitaxel) for 2–3 min on ice, and fixed in methanol at
220C for at least 20 min. The fixed cells were incubated
with mouse monoclonal anti-a-tubulin antibody DM1A
(1:100, Sigma–Aldrich) and/or affinity purified rabbit poly-
clonal anti-HA antibody (1:50, Bethyl Laboratories, Mont-
gomery, TX) for 30–60 min at 37C in a humid chamber.
After rinsing in PBS, the cells were stained with 1:50 dilu-
tions of Alexa 594-conjugated goat anti-mouse IgG and/or
Alexa 488-conjugated goat anti-rabbit IgG (Invitrogen) and
1 mg ml21 DAPI. The microtubules were visualized using
an Optiphot microscope equipped with epifluorescence and
a 603 objective (Nikon, Melville, NY). Images were cap-
tured using a Magnafire digital camera (Optronics, Goleta,
CA).
a-Tubulin Sequencing
Genomic DNA was prepared by lysing cells in a buffer con-
taining 20 mM Tris-HCl (pH 8.0), 50 mM KCl, 2.5 mM
MgCl2, and 0.5% Tween 20. Proteinase K was added to a
final concentration of 0.1 mg ml21 and the lysate was
heated to 55C for 45 min. Enzymatic activity was inacti-
vated at 100C for 10 min and the lysate was stored at
220C overnight. For the mutants derived by transfection,
PCR reactions were carried out using a 50-UTR forward
primer (pTOPF4: 5
0CCC GTA ACC GTG ACC CGC
TGT CTG C30) and a pTOP reverse complementary
primer (pTOPR: 5
0CTA GAA GGC ACA GTC GAG
GCT30). The PCR-amplified products were sequenced
with three primers: (1) a 50-UTR forward primer (pTOPF5:
50CTG TCT GCT TTT GTC ACC30), (2) a forward
primer immediately before the 190th amino acid codon of
the a1-tubulin cDNA sequence (Ca1 190F: 5
0CCC TAC
AAC TCC ATC CTC ACC ACC CAC30), and (3) a
reverse primer complementary to the HA tag (HAtagR:
50CTG TCT GCT TTT GTC ACC30). For mutants
derived by classical genetics, exons 2, 3, and 4 were ampli-
fied by PCR using intron primers specific for Ca1
(GenBank Accession No. AY173017). All PCR-amplified
products were sequenced by the DNA Sequencing Core
Facility (Baylor College of Medicine, Houston, TX).
Confirmation of Paclitaxel Resistance Mutations
Point mutations identified by sequencing were introduced
into pTOPHAa1 using the QuickChange site-directed
mutagenesis kit from Invitrogen. CHO tTA puro 6.6a cells
were transfected with the mutant plasmid and the ability of
the transfected cells to produce colonies in normally toxic
concentrations of paclitaxel was monitored. To enrich for
transfected cells that expressed the mutant cDNAs, the
transfectants were grown in G418 plus 1 mg ml21 tetracy-
cline for 10 days. The G418 resistant cells were trypsinized,
seeded in duplicate wells of six-well dishes containing
300 nM paclitaxel (one well with and one well without 1
mg ml21 tetracycline), and allowed to grow for 10 days. A
third well containing 50-fold fewer cells was grown for 7
days in aMEM with 1 mg ml21 tetracycline but no pacli-
taxel. This third well produced colonies that could be used
to estimate the number of viable cells that were inoculated
into each well. At the end of the experiment the plates were
stained with methylene blue, rinsed with water, and photo-
graphed with a digital camera.
Antibodies and Western Blots
Transfected cells were grown to 80–100% of confluence in
24-well dishes and lysed in 1% SDS. Proteins were precipi-
tated by adding 5 vol. of acetone, centrifuging for 5 min at
12,000 3 g, and resuspending the pellet in 100 ml of sam-
ple buffer (0.0625 M Tris-HCl, pH6.8, 2.5% SDS, 5%
2-mercaptoethanol, 10% glycerol). Proteins were separated
on 7.5% polyacrylamide SDS minigels and transferred to
nitrocellulose membranes (Schleicher and Schuell, Keene,
NH). After blocking the membranes in PBST (PBS with
0.05% Tween 20) containing 3% dry milk, they were incu-
bated in a 1:2,000 dilution of monoclonal antibody DM1A
(Sigma–Aldrich) specific for a-tubulin. A 1:2000 dilution
of anti-actin antibody C4 (Chemicon International, Teme-
cula, CA) was also added as a loading control. The mem-
branes were incubated for 45–60 min at room temperature
and then washed three times in PBST for 10 min each.
Bands were detected by incubating the membranes for
30–45 min in a 1:2000 dilution of peroxidase-conjugated
goat anti-mouse IgG (Sigma–Aldrich) and washing three
times in PBST. Finally, SuperSignal West Pico chemilumi-
nescent substrate (Thermo Fisher Scientific, Rockford, IL)
was added and the membrane was exposed to X-ray film
(Phenix Research Products, Candler, NC).
Quantification of Microtubule Polymer
Cells were grown overnight in triplicate wells of 24-well
dishes containing aMEM and lysed in 100 ml MTB [Min-
otti et al., 1991]. Cell remnants were scraped from the wells
and transferred into 1.5 ml microcentrifuge tubes. The
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wells were rinsed with another 100 ml MTB and this was
combined with the corresponding lysate. To solubilize any
residue, 100 ml of 1% SDS was added to the wells and kept
for later. The lysates were briefly mixed and centrifuged at
12,000 3 g for 15 min at 4C. The supernatants carrying
the unpolymerized tubulin were transferred to fresh tubes.
The pellets containing the polymerized tubulin were resus-
pended in 50 ml water for 20–30 min and combined with
the residues solubilized in SDS from the corresponding
wells. To each sample (supernatant and pellet) 10 ml of a
bacterial lysate containing a GST-tagged a-tubulin was also
added as a quantitative control for possible protein losses
during subsequent steps. Proteins were precipitated using
5 vol. of acetone and resuspended in 100 ml 13 sample
buffer. Equal volumes of samples were resolved on 7.5%
polyacrylamide SDS minigels (BIORAD) and transferred
to nitrocellulose membranes (Schleicher and Schuell). Blots
were incubated with mouse monoclonal antibodies to
a-tubulin (DM1a, Sigma) followed by an Alexa
647-conjugated goat anti-mouse secondary antibody (Invi-
trogen) as described above. Bands were detected with a
Storm imager (Molecular Dynamics, Sunnyvale, CA) and
quantified using Image J. Relative amounts of microtubule
polymer were determined by calculating the a-tubulin to
GST-a-tubulin ratio for the supernatant (free tubulin) and
pellet (polymerized tubulin) from each sample and then cal-
culating the percentage of total tubulin that is in the poly-
mer state by dividing the ratio from the pellet by the sum
of the ratios from the pellet and supernatant fractions and
multiplying by 100.
Two-dimensional Gel Electrophoresis
Cells were metabolically labeled for 1 h in methionine-free
minimum essential medium (Sigma-Aldrich) containing
25 mCi ml21 TRAN35S-LABEL (MP Biomedicals, Solon,
OH). Proteins were then solubilized in 1% SDS, precipi-
tated in 5 vol. of cold ethanol, and resolubilized in 8 M
urea, 5% 2-mercaptoethanol, 2% Triton X-100, 5 mM
Tris-hydrochloride, pH 6.8. The proteins were separated by
two-dimensional gels and transferred to nitrocellulose
membranes using published procedures [Cabral and
Gottesman, 1978; Cabral and Schatz, 1979]. The detection
of a-tubulin on the membranes was accomplished using a
1:2000 dilution of monoclonal antibody DM1A (Sigma–
Aldrich) that specifically recognizes a-tubulin in a wide
range of organisms. The specific identification of acetylated
a-tubulin was carried out using a 1:2000 dilution of mono-
clonal antibody 6–11b-1 (Sigma–Aldrich) that recognizes
a-tubulin acetylated at residue lysine-40 [LeDizet and
Piperno, 1987; Piperno et al., 1987]. The protein spots
were visualized using a peroxidase conjugated goat anti-
mouse IgG (1:2000 dilution, Sigma–Aldrich) and Super-
Signal West Pico chemiluminescent substrate (Thermo
Fisher Scientific). To detect both acetylated and total
a-tubulin simultaneously on the same blots, both primary
antibodies were mixed but the DM1A was further diluted
(1:50,000) to give each antibody a unique staining
appearance.
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